Related references
Note: Only part of the references are listed.Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation
Lan Wu et al.
NATURE CANCER (2020)
Targeted antibody and cytokine cancer immunotherapies through collagen affinity
Jun Ishihara et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Targeting Tumor-Associated Macrophages in Cancer
Paulina Pathria et al.
TRENDS IN IMMUNOLOGY (2019)
Bispecific antibodies: a mechanistic review of the pipeline
Aran F. Labrijn et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Engineering nanoparticles to locally activate T cells in the tumor microenvironment
Dangge Wang et al.
SCIENCE IMMUNOLOGY (2019)
NK Cell Dysfunction and Checkpoint Immunotherapy
Jiacheng Bi et al.
FRONTIERS IN IMMUNOLOGY (2019)
Harnessing innate immunity in cancer therapy
Olivier Demaria et al.
NATURE (2019)
Redirected T Cell Cytotoxicity in Cancer Therapy
Raphael A. Clynes et al.
ANNUAL REVIEW OF MEDICINE, VOL 70 (2019)
Antibodies to watch in 2019
Helene Kaplon et al.
MABS (2019)
Structure, heterogeneity and developability assessment of therapeutic antibodies
Yingda Xu et al.
MABS (2019)
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Jonathan J. Havel et al.
NATURE REVIEWS CANCER (2019)
Macrophages as regulators of tumour immunity and immunotherapy
David G. DeNardo et al.
NATURE REVIEWS IMMUNOLOGY (2019)
Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells
William R. Strohl et al.
ANTIBODIES (2019)
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
Terry J. Fry et al.
NATURE MEDICINE (2018)
A Dual Immunotherapy Nanoparticle Improves T-Cell Activation and Cancer Immunotherapy
Yu Mi et al.
ADVANCED MATERIALS (2018)
Mechanisms of resistance to immune checkpoint inhibitors
Russell W. Jenkins et al.
BRITISH JOURNAL OF CANCER (2018)
Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies
Shetal A. Patel et al.
IMMUNITY (2018)
Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity
Qing Zhang et al.
NATURE IMMUNOLOGY (2018)
The promise and challenges of immune agonist antibody development in cancer
Patrick A. Mayes et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
CARs versus BiTEs: A Comparison between T Cell-Redirection Strategies for Cancer Treatment
Clare Y. Slaney et al.
CANCER DISCOVERY (2018)
Programming CAR-T cells to kill cancer
Louai Labanieh et al.
NATURE BIOMEDICAL ENGINEERING (2018)
Conjugation of haematopoietic stem cells and platelets decorated with anti-PD-1 antibodies augments anti-leukaemia efficacy
Quanyin Hu et al.
NATURE BIOMEDICAL ENGINEERING (2018)
Redirecting T cells to hematological malignancies with bispecific antibodies
Mireya Paulina Velasquez et al.
BLOOD (2018)
The making of bispecific antibodies
Ulrich Brinkmann et al.
MABS (2017)
Site-selective orientated immobilization of antibodies and conjugates for immunodiagnostics development
Min Shen et al.
METHODS (2017)
Therapeutic T cell engineering
Michel Sadelain et al.
NATURE (2017)
Multivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy
Hengfeng Yuan et al.
NATURE NANOTECHNOLOGY (2017)
An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors
Takahiro Ishiguro et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Interferon-γ derived from cytotoxic lymphocytes directly enhances their motility and cytotoxicity
Purnima Bhat et al.
CELL DEATH & DISEASE (2017)
Dual Targeting Nanoparticle Stimulates the Immune System To Inhibit Tumor Growth
Alyssa K. Kosmides et al.
ACS NANO (2017)
Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism
C. Krupka et al.
LEUKEMIA (2016)
CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer
Kipp Weiskopf et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Targeting natural killer cells in cancer immunotherapy
Camille Guillerey et al.
NATURE IMMUNOLOGY (2016)
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
Danny N. Khalil et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
NK cells and cancer: you can teach innate cells new tricks
Maelig G. Morvan et al.
NATURE REVIEWS CANCER (2016)
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Suzanne L. Topalian et al.
CANCER CELL (2015)
Macrophages are critical effectors of antibody therapies for cancer
Kipp Weiskopf et al.
MABS (2015)
Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK
Idit Sagiv-Barfi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Perforin and granzymes: function, dysfunction and human pathology
Ilia Voskoboinik et al.
NATURE REVIEWS IMMUNOLOGY (2015)
Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy
Carola H. Ries et al.
CANCER CELL (2014)
Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells
Liza B. John et al.
CLINICAL CANCER RESEARCH (2013)
Matching cellular dimensions with molecular sizes
Michael Reth
NATURE IMMUNOLOGY (2013)
Taking Advantage of Unspecific Interactions to Produce Highly Active Magnetic Nanoparticle - Antibody Conjugates
Sara Puertas et al.
ACS NANO (2011)
Innate or Adaptive Immunity? The Example of Natural Killer Cells
Eric Vivier et al.
SCIENCE (2011)
Structure and function of immunoglobulins
Harry W. Schroeder et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2010)
Monoclonal antibodies: versatile platforms for cancer immunotherapy
Louis M. Weiner et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Bispecific T-Cell Engaging Antibodies for Cancer Therapy
Patrick A. Baeuerle et al.
CANCER RESEARCH (2009)
Directional conjugation of antibodies to nanoparticles for synthesis of multiplexed optical contrast agents with both delivery and targeting moieties
S. Kumar et al.
NATURE PROTOCOLS (2008)